News

Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells® to Treat Pitt Hopkins Syndrome, a rare form of Autism

Golden, Colorado-November 9, 2021- Vitro Biopharma, Inc. announced receipt of FDA authorization and clearance to enroll patients in its IND for a phase I-II, randomized, double-blind, placebo-controlled study of the safety and efficacy of therapeutic treatment with AlloRx Stem Cells® in children with Pitt Hopkins Syndrome (PTHS), a rare neurogenetic disorder that features autistic traits. PTHS results from genetic mutations/deletions of a key brain development gene, TCF4 (transcription factor 4) that controls neurogenesis.

Vitro Biopharma Acquires Fitore Nutrition and Infinivive MD, Adding Revenues from Innovative Stem Cell Activation Products and Topical Cosmetic Stem Cell Serums

Golden, Colorado-August 31, 2021- Vitro Biopharma, Inc. ("Vitro') announced the acquisition of Fitore Nutrition ("Fitore") and Infinivive MD ("Infinivive"). Fitore, a private company headquartered in Denver, Colorado creates clinically validated supplements and sells them direct to consumers (D2C) via their unique digital marketing platform and SEO expertise.

Infinivive, located in Cherry Creek, Colorado developed the world's first topical cosmetic stem cell serum and is a nationally recognized company led by one of the top industry pioneers in the area of cosmetic surgery, Dr. Jack Zamora M.D.

Vitro Biopharma Signs Multi-Million Dollar Operating Service Contract with European Wellness Biomedical Group

Golden, Colorado-August 19, 2021-Vitro Biopharma, Inc. announced the signing of a contract with European Wellness Biomedical Group headquartered in Kuala Lumpur, Malaysia and it’s start-up subsidiary BioPep being registered in Delaware, USA to develop FDA-approval of biological products derived from existing mitochondrial peptide extracts now used globally as treatment of various conditions including aesthetic dermatology and skin revitalization, autism spectrum disorders, cardiovascular, metabolic and degenerative disorders, CKD and fertility through its global network of 12 (twelve) biomedical regenerative centers located throughout Europe and Asia Pacific.

Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells® to Treat COVID-19

Vitro Biopharma, Inc. announced receipt of FDA authorization and clearance to enroll patients in its phase I-IIa, randomized, double-blinded, placebo controlled study of the safety and efficacy of therapeutic treatment with AlloRx Stem Cells® in adults with COVID-19. Our Investigational New Drug (IND) application will investigate the clinical effects of AlloRx Stem Cells® by studying safety and efficacy in patients with moderate to severe COVID-19.

Vitro Biopharma Retains Leading Health Care Executive as Acting Director of Regulatory Affairs & Director

Vitro Biopharma, Inc. (formerly Vitro Diagnostics, Inc.) announced the appointment of Dr. Caroline Mosessian, PhD, DRSc, FACMPE, ACHE as its acting Director of Regulatory Affairs. Dr. Mosessian has an extensive background in regulatory science including a PhD, MS and Masters in Healthcare Administration degrees from USC in LA.

Vitro Biopharma Names World Renowned Physician Entrepreneur as its CEO

Golden, Colorado-December 10th, 2020-Vitro Diagnostics, Inc., dba Vitro Biopharma announced the appointment by its Board of Directors of Jack Zamora, MD as its new Chief Executive Officer (“CEO”) and the retention of Dr. James Musick, the current CEO as Chief Science Officer (“CSO”). Dr. Zamora adds new dimensions to Vitro Biopharma’s senior management team.

Critically ill COVID-19 Patient Successfully Treated with Vitro Biopharma’s AlloRx Stem Cells®

Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, jointly with GIOSTAR – a San Diego, California-based institution headed by Dr. Anand Srivastava, a pioneer in stem cell science – announced the results of treatment of a critically ill COVID-19 patient with its lead clinical product AlloRx Stem Cells®.

Vitro Biopharma Signs MOU with GIOSTAR for COVID-19 IND Using AlloRx Stem Cells

Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro entered into an exclusive Memorandum of Understanding (MOU) with Global Institute of Stem Cell Therapy and Research, Inc. (“GIOSTAR”) a leading stem cell research institute based in San Diego, California to jointly partner together for a COVID-19 Investigational New Drug

Vitro Biopharma Submits IND Application to FDA for AlloRx Stem Cell(R) Therapy of COVID-19

Dr. Jim Musick, Ph.D., CEO said, “We are very pleased to have submitted our IND using our expanded regulatory team, including a renown regulatory expert in FDA clinical trial management. We are establishing strong communication channels with FDA officials to facilitate and expedite review of our application as well as subsequent steps to gain full FDA approval of AlloRx Stem Cells^®.

Vitro Biopharma Announces MaloneBailey L.L.P. As Its New Auditors

Golden, Colorado-July20th, 2020-Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced that it has engaged MaloneBailey L.L.P. (Certified Public Accounting Firm www.malonebailey.com ) as its new auditors that will be auditing the company’s consolidated balance sheets as of October 31, 2019 and October 31, 2020,

Investigating Stem Cell Therapy for the Coronavirus COVID-19 Pandemic

Recent umbilical cord stem cell therapies in China to fight the Coronavirus are producing encouraging emergency results. Vitro Biopharma has the highest level of umbilical cord stem cell technology to reduce death rates due to the Coronavirus pandemic.

Potential Stem Cell Therapy for Coronavirus Infection

Vitro Biopharma reports on a potential therapy of Coronavirus (COVID-19) infections by stem cell transplant. While this therapy is not a method to eradicate or cure Coronavirus, there is evidence to support the concept that infected patients.

1 2 Next »